Patent ID: 11883479
Assignee: GENEXINE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 15:
16. A method for treating a human papillomavirus (HPV)-induced cancer patient by combining two distinct treatments for administration to the subject within a common time period of at least 13 weeks, said method comprising a HPV vaccine therapy and an immune checkpoint inhibitor therapy, wherein an immune checkpoint inhibitor is administered multiple times at a first fixed dose and a vaccine is administered multiple times at a second fixed dose; and wherein a first administration of the HPV vaccine and a first administration of the immune checkpoint inhibitor are occurred on day of the at least 13 weeks period, and subsequent administrations of the HPV vaccine and subsequent administration of the immune checkpoint inhibitor are occurred within the common time period,
wherein the HPV-induced cancer is metastatic, recurrent or advanced cervical cancer and the subject has been or is subject to an anti-cancer treatment, said cervical cancer being squamous cell carcinoma or adenocarcinoma;
wherein the HPV is HPV 16, HPV 18, or a combination thereof; and/or
wherein the subject is PD-L1 positive or PD-L1 negative.